Similar companies
Income Statement (USD)
Q1 '24 | QoQ | |
---|---|---|
Revenue | 145M | 367.7% |
Gross Profit | 90M | 9100% |
Cost of Revenue | 55M | 71.9% |
Operating expense | 161M | 32% |
Net Income | -4M | 95.1% |
EBITDA | -13M | 85.2% |
Balance Sheet (USD)
Q1 '24 | QoQ | |
---|---|---|
Total Assets | 1.29B | 18.1% |
Total Liabilities | 586M | 7.4% |
Total Equity | 707M | 53% |
Shares Outstanding | 91M | 20.4% |
Cash Flow (USD)
Q1 '24 | QoQ | |
---|---|---|
Cash from operations | -2M | 97.7% |
Cash from investing | -169M | 703.6% |
Cash from financing | 229M | 7533.3% |
EPS
Financial Highlights for Arcus Biosciences in Q1 '24
Arcus Biosciences reported a revenue of 145M, which is a 367.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 90M, marking a 9100% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 55M, a 71.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 161M, showing a 32% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -4M, showing a 95.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -13M, showing a 85.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Arcus Biosciences with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.